Efficacy and Safety of the Fixed-Dose Combination of Atorvastatin/Fenofibrate Versus Atorvastatin on the Lipid Profile of Patients with Type 2 Diabetes and Dyslipidemia

• Published in: Cardiology and Therapy Vol. 14; no. 2; pp. 297 - 314
• Main Authors: Padilla-Padilla, Francisco G., Ruiz-Bernes, Lina N., Román-Pintos, Luis M., Peraza-Zaldívar, Juan A., Sander-Padilla, José G., Lugo-Sánchez, Laura A., Rios-Brito, Kevin F., Arguedas-Núñez, María M., Flores-Huanosta, Diana, González-Canudas, Jorge
• Format: Journal Article
• Language: English
• Published: Cheshire Springer Healthcare 01.06.2025; Springer; Springer Nature B.V; Adis, Springer Healthcare
• Subjects: Atorvastatin; Cardiology; Cardiovascular disease; Cholesterol; Combination therapy; Diabetes; Dosage and administration; Drug dosages; Drug therapy; Drug therapy, Combination; Dyslipidemias; Fenofibrate; Fixed-dose combination; Glucose; High density lipoprotein; Internal Medicine; Lifestyles; Lipids; Lipoproteins; Medical prognosis; Medicine; Medicine & Public Health; Metabolic disorders; Original Research; Pancreatitis; Patient outcomes; Statins; Triglycerides; Type 2 diabetes; Mexico; Type 2 diabetes; Fenofibrate; Atorvastatin; Triglycerides; Dyslipidemias; Fixed-dose combination

Introduction In dyslipidemia associated with type 2 diabetes (T2DM), elevated triglycerides (TG), increased low-density lipoprotein cholesterol (LDL-C), and decreased high-density lipoprotein cholesterol (HDL-C) levels are commonly found, resulting in a high prevalence of mixed dyslipidemia among pa...